# Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Source: https://onco.cc/trials/nct04699188/  
OnCo record `nct04699188` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of JDQ443, TNO155 and Tislelizumab in non-small-cell lung cancer and colorectal cancer, run by Novartis Pharmaceuticals, active and no longer recruiting.

## Summary

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation is a phase 1/2 interventional study registered as NCT04699188 by Novartis Pharmaceuticals, with 344 participants enrolled, started 2021-02-24 and due to reach its primary completion in 2027-01-25. Interventions recorded: JDQ443, TNO155 and tislelizumab.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04699188
- Phase: 1/2
- Setting: A Phase Ib/II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
- Sponsor: Novartis Pharmaceuticals
- Enrolled: 344

## Sources

- ClinicalTrials.gov NCT04699188: https://clinicaltrials.gov/study/NCT04699188

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [JDQ443](https://onco.cc/drugs/jdq443/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/), [TNO155](https://onco.cc/drugs/tno155/)
- companies: [Advanced Accelerator Applications (Novartis)](https://onco.cc/companies/advanced-accelerator-applications/)

---
JSON: https://onco.cc/api/v1/entities/nct04699188.json